H.C. Wainwright slashes price target on Acorda Therapeutics Inc. [ACOR] – find out why.

Related

Share

Acorda Therapeutics Inc. [NASDAQ: ACOR] slipped around -0.1 points on Tuesday, while shares priced at $0.97 at the close of the session, down -8.89%. Acorda Therapeutics Inc. stock is now -52.21% down from its year-to-date (YTD) trading value. ACOR Stock saw the intraday high of $1.03 and lowest of $0.95 per share. The company’s 52-week high price is 8.08, which means current price is +39.25% above from all time high which was touched on 01/07/20.

Compared to the average trading volume of 1.83M shares, ACOR reached a trading volume of 2956000 in the most recent trading day, which is why market watchdogs consider the stock to be active.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


What do top market gurus say about Acorda Therapeutics Inc. [ACOR]?

H.C. Wainwright have made an estimate for Acorda Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 14, 2019. The new note on the price target was released on May 23, 2019, representing the official price target for Acorda Therapeutics Inc. stock. On August 07, 2018, analysts increased their price target for ACOR shares from 15 to 25.

The Average True Range (ATR) for Acorda Therapeutics Inc. is set at 0.08, with the Price to Sales ratio for ACOR stock in the period of the last 12 months amounting to 0.26. The Price to Book ratio for the last quarter was 0.15, with the Price to Cash per share for the same quarter was set at 1.74.

How has ACOR stock performed recently?

Acorda Therapeutics Inc. [ACOR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 26.92. With this latest performance, ACOR shares gained by 23.81% in over the last four-week period, additionally sinking by -42.99% over the last 6 months – not to mention a drop of -87.21% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACOR stock in for the last two-week period is set at 60.03, with the RSI for the last a single of trading hit 65.65, and the three-weeks RSI is set at 54.80 for Acorda Therapeutics Inc. [ACOR]. The present Moving Average for the last 50 days of trading for this stock 0.9032, while it was recorded at 0.8621 for the last single week of trading, and 1.8306 for the last 200 days.

Acorda Therapeutics Inc. [ACOR]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Acorda Therapeutics Inc. [ACOR] shares currently have an operating margin of -60.60 and a Gross Margin at +68.56. Acorda Therapeutics Inc.’s Net Margin is presently recorded at -141.87.

Return on Total Capital for ACOR is now -14.84, given the latest momentum, and Return on Invested Capital for the company is -35.39. Return on Equity for this stock declined to -59.16, with Return on Assets sitting at -24.82. When it comes to the capital structure of this company, Acorda Therapeutics Inc. [ACOR] has a Total Debt to Total Equity ratio set at 88.16. Additionally, ACOR Total Debt to Total Capital is recorded at 46.85, with Total Debt to Total Assets ending up at 30.45. Long-Term Debt to Equity for the company is recorded at 81.99, with the Long-Term Debt to Total Capital now at 43.57.

Reflecting on the efficiency of the workforce at the company, Acorda Therapeutics Inc. [ACOR] managed to generate an average of -$793,506 per employee. Receivables Turnover for the company is 8.46 with a Total Asset Turnover recorded at a value of 0.17.Acorda Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.40.

Earnings analysis for Acorda Therapeutics Inc. [ACOR]

With the latest financial reports released by the company, Acorda Therapeutics Inc. posted -0.55/share EPS, while the average EPS was predicted by analysts to be reported at -1.06/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 48.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACOR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Acorda Therapeutics Inc. go to 29.00%.

Insider trade positions for Acorda Therapeutics Inc. [ACOR]

There are presently around $46 million, in the hands of institutional investors. The top three institutional holders of ACOR stocks are: BLACKROCK INC. with ownership of 7,321,920, which is approximately -6.598% of the company’s market cap and around 1.49% of the total institutional ownership; FMR LLC, holding 5,191,573 shares of the stock with an approximate value of $5.55 million in ACOR stocks shares; and VANGUARD GROUP INC, currently with $4.74 million in ACOR stock with ownership of nearly -12.147% of the company’s market capitalization.

44 institutional holders increased their position in Acorda Therapeutics Inc. [NASDAQ:ACOR] by around 2,878,034 shares. Additionally, 71 investors decreased positions by around 12,447,142 shares, while 24 investors held positions by with 27,740,244 shares. The mentioned changes placed institutional holdings at 43,065,420 shares, according to the latest SEC report filing. ACOR stock had 10 new institutional investments in for a total of 1,190,309 shares, while 30 institutional investors sold positions of 2,038,690 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam